FIELD: biotechnology.
SUBSTANCE: process for purifying a recombinant polypeptide produced in Chinese hamster ovary host cells characterized by levels of phospholipase B-like enzyme 2 (PLBL2) above 100 ng/mg, including a hydrophobic interaction chromatography (HIC) stage is described, where the method provides a purified preparation including a recombinant polypeptide and residual hamster PLBL2.
EFFECT: invention expands the arsenal of methods for purifying recombinant polypeptides.
29 cl, 7 dwg, 16 tbl, 3 ex
| Title | Year | Author | Number |
|---|---|---|---|
| ANTIBODIES WITH REDUCED BINDING WITH TECHNOLOGICAL IMPURITIES | 2017 |
|
RU2771330C2 |
| NEW ANTI-IL13 ANTIBODIES AND USE THEREOF | 2020 |
|
RU2752833C1 |
| BISPECIFIC TRIVALENT ANTIBODIES BINDING TO CLAUDIN 6 OR CLAUDIN 18.2 AND CD3 FOR THE TREATMENT OF ONCOLOGICAL DISEASES WITH CLAUDIN EXPRESSION | 2017 |
|
RU2798988C2 |
| IL4/IL13 RECEPTOR MOLECULE FOR VETERINARY USE | 2018 |
|
RU2795591C2 |
| ANTI-IL31 ANTIBODIES FOR VETERINARY USE | 2018 |
|
RU2795485C2 |
| MOLECULES BINDING WITH CD38 AND PD-L1 | 2017 |
|
RU2764201C2 |
| ANTI-MESOTHELIN ANTIBODY AND CONJUGATE THEREOF WITH MEDICINAL PRODUCTS | 2019 |
|
RU2747995C1 |
| CD40L ANTIBODIES AND METHODS OF TREATING CD40L RELATED DISEASES AND DISORDERS | 2016 |
|
RU2727646C2 |
| INTRODUCTION OF CONSTRUCTED T CELLS FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM CANCER | 2017 |
|
RU2757308C2 |
| ANTI-PD-1 ANTIBODIES | 2017 |
|
RU2752832C2 |
